Trigliserit-Glikoz İndeksi, kolorektal kanserin yeni bir belirleyicisidir

Yıl 2024, Cilt: 8 Sayı: 1, 44 - 49, 30.04.2024

Erkan Aksoy , Zeynep Ergenç , Hasan Ergenç , Feyzi Gökosmanoğlu

https://doi.org/10.34084/bshr.1311813

Öz

Amaç: Kolorektal kanser, kansere bağlı ölümlerin önde gelen nedenidir. Metabolik sendrom, obezite, pre-diyabet ve dislipidemi ile ilişkilidir. Çalışmanın amacı, yeni bir biyobelirteç olarak TyG İndeksinin KRK riski üzerindeki etkilerini araştırmaktır.

Gereç ve Yöntem: Çalışma, KRK (n=124) ve Kontrol Grubu (n=132) olmak üzere toplam 256 kişi ile gerçekleştirildi. TyG İndeksi, Ln [açlık TG'ler (mg/dL) x açlık glikozu (mg/dL)/2] formülü ile açlık trigliseritleri ve glukoz kullanılarak hesaplandı. TyG İndeksinin CRC varlığını tahmin etme performansı da değerlendirildi.

Bulgular: İnsülin direnci ile ilişkili metabolik parametrelerin KRK Grubunda istatistiksel olarak anlamlı düzeyde olduğu bulundu. Açlık plazma glukozu, trigliserit, insülin, hemoglobin A1c ve GGT de istatistiksel olarak anlamlıydı. TyG Index'in KRK varlığı için cut-off değerinin de 4,49 olduğu saptandı (EAA=0,782, sensitivite %77, spesifite=%78,4 ve p=0,002).

Sonuç: Bu çalışmada, TyG İndeksinin KRK riski ile ilişkili olduğu ve yüksek riskli KRK olgularında yeni bir biyobelirteç olarak kullanılabileceği bulundu.

Anahtar Kelimeler

TyG İndeksi, Kolorektal kanser, İnsülin direnci

Destekleyen Kurum

yoktur

Proje Numarası

yoktur

Teşekkür

yoktur

Triglyceride-Glucose Index is a novel predictor of colorectal cancer

Öz

Aim: Colorectal cancer is the leading cause of cancer-related mortality. Metabolic syndrome is associated with obesity, pre-diabetes, and dyslipidemia. The purpose of the study was to investigate the effects of TyG Index as a novel biomarker on CRC risk.

Material and Method: The study was conducted with 256 people in total, including the CRC (n=124) and Control Groups (n=132). TyG Index was calculated by using fasting triglycerides and glucose with the formula Ln [fasting TGs (mg/dL) x fasting glucose (mg/dL)/2]. The performance of the TyG Index to predict the presence of CRC was also evaluated.

Results: Metabolic parameters associated with insulin resistance were found to be at statistically significant levels in the CRC Group. Fasting plasma glucose, triglyceride, insulin, hemoglobin A1c, and GGT were also statistically significant. It was also determined that the cut-off value of the TyG Index for the presence of CRC was 4.49 (AUC = 0.782, sensitivity 77%, specificity = 78.4%, and p=0.002).

Conclusion: In the present study, it was found that the TyG Index is associated with the risk of CRC and can be used as a novel biomarker in high-risk CRC cases.

Anahtar Kelimeler

TyG Index, Colorectal cancer, Insulin resistance.

Proje Numarası

yoktur

Kaynakça

• Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78. doi: 10.3322/caac.20038. PMID: 19897840.
• Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila). 2011;4(11):1873-83. doi: 10.1158/1940-6207.CAPR-11-0218. Epub 2011 Jun 22. PMID: 21697276.
• Bogazzi F, Ultimieri F, Raggi F, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004;150(6):863-75. doi: 10.1530/eje.0.1500863. PMID: 15191358.
• Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA, et al. Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol. 2006;4(12):1514-21. doi: 10.1016/j.cgh.2006.09.014. PMID: 17162243; PMCID: PMC1766481.
• Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304. doi: 10.1089/met.2008.0034. PMID: 19067533.
• Hameed EK. TyG Index a promising biomarker for glycemic control in type 2 Diabetes Mellitus. Diabetes Metab Syndr. 2019;13(1):560-563. doi: 10.1016/j.dsx.2018.11.030. Epub 2018 Nov 10. PMID: 30641766.
• Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304. doi: 10.1089/met.2008.0034. PMID: 19067533.
• Salgado AL, Carvalho Ld, Oliveira AC, et al. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010;47(2):165-9. doi: 10.1590/s0004-28032010000200009. PMID: 20721461.
• Tastanoğlu H, Çelik N. Triglyceride-Glucose index as a surrogate marker for insulin resistance in obese adolescents. Cumhuriyet Medical Journal. 2021; 43(4), 355-363.
• Avcı Y, Demir AR, Güler A, et al. Triglyceride-glucose index is associated with residual SYNTAX score in patients with ST-segment elevation myocardial infarction. Cukurova Medical Journal. 2023; 48(1), 92-100
• Altun Ö, Kalyon S. The Role of Triglyceride-HDL Ratio and Triglyceride-glucose Index in Estimating Glycemic Control in Patients with Type 2 Diabetes Mellitus. Meandros Medical & Dental Journal. 2023; 23(1).
• Ergenc Z, Erhenc H, Oflaz S. Association Between Triglyceride Glucose Index and Neutrophil Lymphocyte Ratio in Patients with Gonarthrosis. Sakarya Tıp Dergisi. 2023; 13(1), 41-47.
• Akyüzlü ZN, Mutlu HH. Tiroit hastalığı olanlarda trigliserit/glikoz indeksi insülin direnci belirteci olarak kullanılabilir mi?. Ege Tıp Dergisi. 2020; 59(3), 165-173.
• Zou S, Xu Y. Association of the triglyceride-glucose index and major adverse cardiac and cerebrovascular events in female patients undergoing percutaneous coronary intervention with drug-eluting stents: A retrospective study. Diabetes Res Clin Pract. 2021;181:109073. doi: 10.1016/j.diabres.2021.109073. Epub 2021 Sep 27. PMID: 34592393.
• Beran A, Ayesh H, Mhanna M, et al. Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals. J Clin Med. 2022;11(9):2666. doi: 10.3390/jcm11092666. PMID: 35566790; PMCID: PMC9102411.
• Navarro-González D, Sánchez-Íñigo L, Pastrana-Delgado J, et al. Triglyceride-glucose index (TyG Index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort. Prev Med. 2016;86:99-105. doi: 10.1016/j.ypmed.2016.01.022. Epub 2016 Feb 5. PMID: 26854766.
• Okamura T, Hashimoto Y, Hamaguchi M, et al. Triglyceride-glucose index (TyG Index) is a predictor of incident colorectal cancer: a population-based longitudinal study. BMC Endocr Disord. 2020;20(1):113. Published 2020 Jul 24. doi:10.1186/s12902-020-00581-w.
• Ortiz AP, Thompson CL, Chak A, et al. Insulin resistance, central obesity, and risk of colorectal adenomas. Cancer. 2012;118(7):1774-1781. doi:10.1002/cncr.26454
• Friedrich N, Thuesen B, Jørgensen T, et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35(4):768-73. doi: 10.2337/dc11-1833. Epub 2012 Feb 28. PMID: 22374641; PMCID: PMC3308317.
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-91. doi: 10.1038/nrc1408. PMID: 15286738.
• Yamamoto S, Nakagawa T, Matsushita Y, et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care. 2010;33(1):184-9. doi: 10.2337/dc09-1197. Epub 2009 Oct 16. PMID: 19837793; PMCID: PMC2797970.
• Ashbeck EL, Jacobs ET, Martínez ME, et al. Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1134-43. doi: 10.1158/1055-9965.EPI-08-1015. Epub 2009 Mar 24. PMID: 19318435; PMCID: PMC2737414.
• Tsilidis KK, Brancati FL, Pollak MN, et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control. 2010;21(1):1-10. doi:10.1007/s10552-009-9428-6.
• Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3(9):1077-83. doi: 10.1158/1940-6207.CAPR-10-0186. Epub 2010 Sep 1. PMID: 20810669.
• Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28-36. doi: 10.1002/cncr.21950. PMID: 16721800.